Biodexa Pharmaceuticals Files 6-K Report
Ticker: BDRX · Form: 6-K · Filed: Feb 13, 2025 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | Feb 13, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Biodexa Pharma (fka Midatech) filed a 6-K on Feb 13, 2025. Standard foreign issuer report.
AI Summary
Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on February 13, 2025. The filing is a report of a foreign private issuer for the month of February 2025. The company is incorporated in the UK and its principal executive office is located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ.
Why It Matters
This filing indicates ongoing reporting requirements for Biodexa Pharmaceuticals PLC as a foreign private issuer, providing transparency to investors about its regulatory status.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific financial or operational news that would indicate a change in risk.
Key Players & Entities
- Biodexa Pharmaceuticals PLC (company) — Registrant
- Midatech Pharma Plc (company) — Former company name
- February 13, 2025 (date) — Filing date
- 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ (location) — Principal executive office address
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.
When was Biodexa Pharmaceuticals PLC formerly known as?
Biodexa Pharmaceuticals PLC was formerly known as Midatech Pharma Plc, with a date of name change on June 2, 2015.
What is the principal executive office address of Biodexa Pharmaceuticals PLC?
The principal executive office address is 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
Does Biodexa Pharmaceuticals PLC file annual reports under Form 20-F or Form 40-F?
Biodexa Pharmaceuticals PLC indicates it files annual reports under Form 20-F.
What is the SIC code for Biodexa Pharmaceuticals PLC?
The Standard Industrial Classification (SIC) code for Biodexa Pharmaceuticals PLC is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 245 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2025-02-13 08:30:37
Filing Documents
- f6k_021325.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 5KB
- 0001171843-25-000804.txt ( ) — 12KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC (Registrant) Date: February 13, 2025 /s/ Stephen Stamp Stephen Stamp Chief Executive Officer, Chief Financial Officer